Day One Biopharmaceuticals (NASDAQ:DAWN) Releases Earnings Results, Beats Estimates By $0.58 EPS

Day One Biopharmaceuticals (NASDAQ:DAWN) issued its earnings results on Wednesday. The company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.58, Briefing.com reports. The firm had revenue of $93.76 million during the quarter, compared to the consensus estimate of $15.05 million. During the same period in the previous year, the firm earned ($0.54) earnings per share.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN traded up $0.51 on Thursday, reaching $14.98. The stock had a trading volume of 1,553,604 shares, compared to its average volume of 924,070. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -7.42 and a beta of -1.51. The company has a 50-day simple moving average of $14.16 and a 200-day simple moving average of $14.38. Day One Biopharmaceuticals has a 12-month low of $10.90 and a 12-month high of $18.07.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday. Bank of America upgraded shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and lifted their price objective for the company from $11.00 to $24.00 in a report on Thursday, August 1st. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday. JPMorgan Chase & Co. cut their price target on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, Piper Sandler reissued an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Monday, July 8th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $35.71.

Insiders Place Their Bets

In related news, insider Samuel C. Blackman sold 2,232 shares of the stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $31,248.00. Following the completion of the transaction, the insider now directly owns 1,127,535 shares in the company, valued at $15,785,490. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Samuel C. Blackman sold 30,000 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total value of $426,600.00. Following the completion of the transaction, the insider now owns 1,097,535 shares in the company, valued at $15,606,947.70. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Samuel C. Blackman sold 2,232 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $31,248.00. Following the transaction, the insider now directly owns 1,127,535 shares of the company’s stock, valued at $15,785,490. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 48,748 shares of company stock worth $689,072. 8.40% of the stock is owned by corporate insiders.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.